• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
opioid epidemic

Johnson & Johnson Accused of Dodging Liability for Its Alleged Role in Opioid Epidemic

By
Jef Feeley
Jef Feeley
and
Bloomberg
Bloomberg
Down Arrow Button Icon
By
Jef Feeley
Jef Feeley
and
Bloomberg
Bloomberg
Down Arrow Button Icon
July 15, 2019, 3:40 PM ET
A used syringe in the dirt.
NEW YORK, NEW YORK - MARCH 13: Hypodermic needles litter the ground in the South Bronx on March 13, 2019 in New York City. America's drug makers are finding themselves under increased legal scrutiny by states and attorney generals as hundreds of lawsuits tied to the deadly opioid epidemic have been filed against them. Pharmacy chains and drug makers such as Purdue Pharma, Johnson & Johnson and CVS are finding their internal documents and research with opioids being used in court against them in lawsuits claiming that they helped to fuel the nationwide epidemic which has killed tens of thousands of Americans. (Photo by Spencer Platt/Getty Images)Spencer Platt–Getty Images

Even after illegally promoting opioid painkillers to reap billions of dollars in profit over the past two decades, Johnson & Johnson has accepted “zero responsibility’’ for its central role in fueling a public-health crisis, Oklahoma’s top law-enforcement official told a trial judge.

J&J engaged in a “cunning” scheme to dupe doctors into over-prescribing addictive medications that “wrecked thousands” of families in the state, Oklahoma Attorney General Mike Hunter said during closing arguments Monday. The trial in Oklahoma City is the first of more than 1,900 local U.S. government lawsuits against drug makers and distributors over the fallout from opioid abuse.

“They blame everyone else,” Hunter told Judge Thad Balkman, who is hearing the case without a jury. “The only question is whether the Oklahoma taxpayer or the kingpin” should pick up the tab for the costs of addressing the state’s epidemic, the attorney general said.

J&J disputes the state’s allegations and refuses to settle the dispute like their rivals. Larry Ottaway, a J&J lawyer, told Balkman the drugmaker is being used as a scapegoat for other companies’ missteps.

“There are no easy answers” to the state’s opioid-addiction problems, and accusing J&J of being “the head of some opioid cartel” isn’t productive, Ottaway said in his closing argument.

At the end of presentations by both sides, Balkman said he will review the evidence and announce his opinion in about a month.

Hunter claims more than 4,000 Oklahomans died over the past two decades from opioid abuse and thousands were left hooked on pills. Similar allegations against market leader Purdue Pharma LP led to a $270 million settlement before the trial began more than a month ago, while Teva Pharmaceutical Industries Ltd. agreed to pay $85 million.

Government officials across the U.S. are seeking to collect billions of dollars as compensation for their costs in dealing with opioid addiction. The outcome in Oklahoma — where J&J is facing allegations under the state’s public-nuisance law — could impact claims and settlement talks involving other states, cities and counties, who are using the same legal theory to hold the drugmaker liable.

Unfair Blame

J&J argues it’s being blamed for the bad acts of others, including Purdue and Teva. New Brunswick, New Jersey-based J&J has also fought the state’s request for as much as $17.5 billion over 30 years in reimbursement for current and future outlays to cope with the epidemic’s costs.

Hunter claims J&J is a “kingpin’’ of the opioid crisis because some of its former overseas units once produced and processed opium poppies used as the active-pharmaceutical ingredient in opioids. J&J officials vigorously rejected such characterizations. The company said it sold those units and that it was hardly the only one growing poppies for medical uses.

“J&J paid ’em to push pills,” Brad Beckworth, a lawyer representing the state, said of the company’s opioid-promotion strategy with doctors. “That’s what drug dealers do.”

Beckworth, the state’s lead lawyer on the case, also described J&J as “a corrupt company” that only cared about making money when it came to promoting and supplying opioids.

Oklahoma’s lawyers presented evidence showing Australian poppy cultivator Tasmanian Alkaloids sold the key ingredient for opioid medications to other manufacturers, including Purdue and Teva.

During the trial, J&J and its Janssen unit provided testimony from an expert on world-wide drug smuggling who rejected the state’s claim that the opioid promotions by the company were similar to those of illegal traffickers.

J&J’s attorney also dismissed the state’s claims the company’s sales reps were tasked with duping Oklahoma doctors into ramping up opioid prescriptions regardless of the risks and lavishly awarded for doing so.

“The state would have you believe we marshaled an army to come here to mislead doctors about risk and benefits of opioids,” Ottaway said. “Not true.”

He also asked Balkman to remember the state didn’t provide evidence from any Oklahoma doctors who could support claims that J&J or Janssen officials misled them about the addiction and overdose risks of opioids.

The case is State of Oklahoma v. Purdue Pharma LP, CJ-2017-816, Cleveland County, Oklahoma, District Court (Norman).

More must-read stories from Fortune:

—Change Healthcare CEO: IPO marks time to change healthcare

—Facebook cracks down on miracle cures and scammy diet pills

—Commentary: Why Alexa gaining medical skills could be bad for health care

—CVS wants to make your drugstore your doctor

—Listen to our new audio briefing, Fortune 500 Daily

Follow Fortune on Flipboard to stay up-to-date on the latest news and analysis.

About the Authors
By Jef Feeley
See full bioRight Arrow Button Icon
By Bloomberg
See full bioRight Arrow Button Icon

Latest in

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.


Most Popular

placeholder alt text
Success
In 2026, many employers are ditching merit-based pay bumps in favor of ‘peanut butter raises’
By Emma BurleighFebruary 2, 2026
1 day ago
placeholder alt text
Politics
Meet the Palm Beach billionaire who paid $2 million for a private White House visit with Trump
By Tristan BoveFebruary 3, 2026
11 hours ago
placeholder alt text
Cybersecurity
Top AI leaders are begging people not to use Moltbook, a social media platform for AI agents: It’s a ‘disaster waiting to happen’
By Eva RoytburgFebruary 2, 2026
1 day ago
placeholder alt text
Future of Work
‘You’re not a hero, you’re a liability’: Shark Tank’s Kevin O’Leary warns Gen Z founders to stop glorifying hustle culture
By Jacqueline MunisFebruary 2, 2026
1 day ago
placeholder alt text
Personal Finance
Current price of silver as of Monday, February 2, 2026
By Joseph HostetlerFebruary 2, 2026
2 days ago
placeholder alt text
Economy
'I just don't have a good feeling about this': Top economist Claudia Sahm says the economy quietly shifted and everyone's now looking at the wrong alarm
By Eleanor PringleJanuary 31, 2026
4 days ago

Latest in

Startups & VentureElon Musk
Nevada legislators blast Boring Company over safety and environmental violations as Elon Musk-owned startup declines to testify in hearing
By Jessica MathewsFebruary 3, 2026
52 minutes ago
AIAmazon
Amazon AWS CEO Matt Garman pushes back against Elon Musk’s space data centers plan
By Alexei OreskovicFebruary 3, 2026
4 hours ago
Lurie stands a podium and addresses a crowd.
SuccessSuper Bowl
Levi Strauss heir Daniel Lurie helped lure the Super Bowl when Levi’s Stadium was under construction. Now he’s mayor for the $440 million windfall
By Jacqueline MunisFebruary 3, 2026
5 hours ago
Man wearing sunglasses and a collared shirt.
C-Suitechief executive officer (CEO)
New Disney CEO Josh D’Amaro stands to make $45 million, but he’ll also get something priceless—a ‘clean break’ with Bob Iger
By Amanda GerutFebruary 3, 2026
5 hours ago
C-SuiteSuccession
Bob Iger left Disney’s CEO post just before COVID exploded. Will his second exit be followed by a plot twist?
By Geoff ColvinFebruary 3, 2026
5 hours ago
An aerial view of America’s only rare earths mine
EnergyRare Earth Metal
New ‘Project Vault’ critical minerals stockpile is ‘first step of many’ needed for U.S. to break China’s supply-chain chokehold
By Jordan BlumFebruary 3, 2026
6 hours ago